基本信息
浏览量:372
职业迁徙
个人简介
Dr Dick de Zeeuw earned his MD from the University of Groningen in 1975. His finished his PhD thesis in 1980 on the topic of renal hypertension in the Renal Department of the Groningen University. Trained in clinical and experimental renal research at the Renal Department in Groningen, and trained in Clinical Pharmacology at the University of Dallas (1984-1985). He was Board Certified in 1996 at the University of Groningen. Dr de Zeeuw is currently Professor and Chair of the Research Section of the Department of Clinical Pharmacy and Pharmacology.
He serves (served) on the editorial board of several international journals, including Kidney International, Journal of Hypertension, JRAAS, Current Opinion in Nephrology and Hypertension, Journal of Geriatric Urology and Nephrology, NEPHRON, Clinical Nephrology, Clinical Kidney Journal, European Journal Preventive Cardiology.
He is Director of the Groningen University Institute for Drug Exploration (GUIDE), and member of International Society of Nephrology Council.
His research interests include: optimize the current and find new therapy approaches to reduce the progressive loss of cardiovascular and renal function, both in diabetic and non-diabetic renal disease. The role of albuminuria/proteinuria and microalbuminuria as biomarker for cardiac and renal disease progression has his particular interest, not only trying to establish the independent “causal” role of albumin leakage in renal and cardiovascular disease progression, but also to establish intervention strategies that lower albuminuria/proteinuria with the supposed organ protective results. In his “albuminuria” quest he initiated large cohort studies such as PREVEND (general population) and GIANTT (type 2 diabetes), and was/is involved in the leadership of several clinical trials on preventing diabetic cardiovascular and renal progression such as RENAAL (AII receptor antagonist), PLANET (statin), TREAT (EPO), VITAL (vitD), SUN (sulodexide), ALTITUDE (renin-inhibition), CANVAS and CREDENCE (SGLT2-inhibition), RADAR and SONAR (atrasentan), BEACON (bardoxolone).
Unraveling the reasons for individual therapy resistance and creating a response score to evaluate the total effect of drugs are the topics that he judges to be the important focus for the next decades.
研究兴趣
论文共 485 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
引用0浏览0WOS引用
0
0
David Z I Cherney,Dick de Zeeuw,Hiddo J L Heerspink, Jose Cardona, Marc Desch, Arne Wenz,Friedrich Schulze,Masaomi Nangaku
Diabetes, obesity & metabolismno. 8 (2023): 2218-2226
Katherine R. Tuttle, Frederik Persson,Lisa Cronin,Sibylle J. Hauske, Javaid Hussain,Dick de Zeeuw,Hiddo Lambers Heerspink
Nephrology Dialysis Transplantationno. Supplement_1 (2023)
引用1浏览0引用
1
0
Jie Yu,Arianne N Sweeting, Chris Gianacas,Lauren Houston,Vivian Lee,Robert A Fletcher,Vlado Perkovic,Qiang Li,Brendon L Neuen, Otavio Berwanger,Hiddo J L Heerspink,Dick de Zeeuw,
引用0浏览0WOS引用
0
0
American journal of kidney diseases : the official journal of the National Kidney Foundationno. 1 (2023): 84-96.e1
NEPHROLOGY DIALYSIS TRANSPLANTATION (2023): I652-I652
引用0浏览0引用
0
0
American journal of nephrology (2023)
引用0浏览0WOS引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn